Valuation: PTC Therapeutics, Inc.

Market Cap 7.04B 6.16B 5.68B 5.24B 9.95B 671B 10.12B 67.85B 26.64B 331B 26.43B 25.85B 1,137B P/E 2026 *
93.8x
P/E 2027 * 33.2x
Enterprise Value 5.25B 4.6B 4.24B 3.92B 7.43B 501B 7.55B 50.65B 19.89B 247B 19.73B 19.3B 849B EV / Sales 2026 *
4.46x
EV / Sales 2027 * 3.94x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-5.25%
1 week+1.85%
Current month+4.02%
1 month+12.92%
3 months+23.53%
6 months+9.36%
Current year+11.70%
1 week 83.83
Extreme 83.83
90.87
1 month 71.8
Extreme 71.8
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
07-07Fiscal year

Chief Technology Officer

73,839 0.0890%
07-06Fiscal year

General Counsel

15,197 0.0183%
06-26Fiscal year

Chief Technology Officer

24,390 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-5.25%+1.85%+74.77%+111.33% 7.04B
-2.33%-2.09%+49.88%+169.76% 1,060B
-0.82%-2.30%+63.79%+62.56% 619B
-0.73%-4.98%+28.91%+83.79% 438B
+0.33%-1.17%+31.07%+26.57% 333B
-0.02%-2.85%+29.15%+46.14% 282B
-3.89%-11.22%+22.81%+25.23% 267B
+0.66%-1.42%-26.59%-37.67% 218B
-0.06%-2.88%+23.07%+61.02% 196B
-3.72%-1.10%+18.41%+69.98% 161B
Average -1.58%-2.82%+31.53%+61.87% 358.09B
Weighted average by Cap. -1.32%-3.09%+36.82%+83.71%

Financials

2026 *2027 *
Net sales 1.18B 1.03B 949M 877M 1.66B 112B 1.69B 11.34B 4.45B 55.29B 4.42B 4.32B 190B 1.32B 1.15B 1.06B 983M 1.86B 126B 1.9B 12.71B 4.99B 61.97B 4.95B 4.84B 213B
Net income 69.83M 61.08M 56.34M 52.03M 98.73M 6.66B 100M 673M 264M 3.28B 262M 256M 11.28B 186M 162M 150M 138M 262M 17.69B 267M 1.79B 702M 8.72B 697M 681M 29.97B
Net Debt -1.78B -1.56B -1.44B -1.33B -2.52B -170B -2.56B -17.2B -6.75B -83.81B -6.7B -6.55B -288B -1.84B -1.61B -1.48B -1.37B -2.6B -176B -2.65B -17.74B -6.97B -86.47B -6.91B -6.76B -297B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
10/07/26 $84.85 -5.25% 1,066,837
09/07/26 $89.55 +1.11% 1,269,804
08/07/26 $88.57 -0.71% 1,328,349
07/07/26 $89.20 +4.40% 1,410,794
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
84.85USD
Average target price
94.14USD
Spread / Average Target
+10.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock